Pharma simplifies dosing, failing patients on precise-exposure drugs
Ranvir Mangat · Precision Dosing & AI in Healthcare: InsightRx’s Journey to Transform Medication Personalization · Aug 22, 2025 · at 3:12
Ranvir Mangat, co-founder and COO of precision dosing software company InsightRx, explains how standard pharmaceutical development leads to one-size-fits-all dosing regimens.
0:00 / 0:43exact quote · 43.1s
720p mp4 · rendered on demand · StarZero watermark
“Part of the issue is, in that process, they have to try and make it, you know, somewhat simple, so that when it goes into the real world, into the clinic, it's easy for the mass population to follow that dosing guidance, and that's okay with certain drugs that we call them, they have a wide therapeutic index, so, you know, it doesn't really matter the dosing, Makes a difference, but there's a wide band where if you dose too much, you know, you may not have an adverse event, or if you dose too low, you may have some lack of efficacy, but there's a whole bunch of drugs where it's really important on the exposure that patient receives, and there you want to optimize the outcome.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Ranvir Mangat
Mangat: Generative AI will rewrite software across every industry vertical
“I think you're going to see Pretty much every software, every industry vertical be kind of rewritten around and a gen AI native stack or user interface or technology stack.”
Mangat: Hospital Pharmacy ROI Is Challenging Because Savings Accrue to Other Budgets
“When you're in healthcare, it's in our case, we're selling to the pharmacy and the pharmacy is more of a cost center. So trying to translate sometimes to the fact that maybe you're saving on adverse events that goes to someone else's budget or maybe the CMO. S…”
Mangat: Selling to Health Insurers Requires Massive Scale and Major Cost Problems
“If you're dealing with insurance companies, you know, they are, in our experience, they are looking at their top 10 problems, or even their top five problems, and the amount of scale you need to have to be able to have a value prop for an insurance company, it…”
Mangat: AI workflows will require humans in loop until AGI
“I still think though, that you're always going to have a, Human in the loop. Maybe for another, I, you know, I'm not going to project how many five years, how many years, five years or 10 years, but, you know, until you get that AGI that happens you know, ther…”